MDX-210 humanized bispecific antibody: Began a Phase I/II trial in 30 patients who have resisted conventional treatment

Medarex Inc. (MEDX), Annandale, N.J. Product: MDX-210 humanized bispecific antibody Indication: Metastatic prostate cancer Status: Began a Phase I/II trial in 30 patients who have resisted conventiona...